Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.
British journal of pharmacology • Vol. 144, Issue 6 • 2005
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
The Journal of pharmacology and experimental therapeutics • Vol. 303, Issue 3 • 2002
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Pharmacogenetics • Vol. 11, Issue 6 • 2001
Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.
Neuropharmacology • Vol. 41, Issue 4 • 2001
